IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITP IT Tech Packaging Inc

Post-Mkt 03-23 18:27:35 EDT

0.1815

+0.0053

+3.04%

盘后0.1788

-0.0027-1.51%

17:25 EDT

High0.1850	Low0.1770	Vol190.68K
Open0.1804	D1 Closing0.1762	Amplitude4.54%
Mkt Cap3.08M	Tradable Cap2.98M	Total Shares16.97M
T/O34.65K	T/O Rate1.16%	Tradable Shares16.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ITP","market":"US","secType":"STK","nameCN":"IT Tech Packaging Inc","latestPrice":0.181548,"timestamp":1774296000000,"preClose":0.1762,"halted":0,"volume":190681,"hourTrading":{"tag":"盘后","latestPrice":0.1788,"preClose":0.181548,"latestTime":"17:25 EDT","volume":17,"amount":3.0450000499999996,"timestamp":1774301118524,"change":-0.002748,"changeRate":-0.015136,"amplitude":0.014872},"delay":0,"changeRate":0.030351872871736615,"floatShares":16423703,"shares":16965420,"eps":-0.861876,"marketStatus":"Post-Mkt","change":0.005348,"latestTime":"03-23 18:27:35 EDT","open":0.1804,"high":0.185,"low":0.177,"amount":34647.50233081,"amplitude":0.045403,"askPrice":0.185,"askSize":5500,"bidPrice":0.17,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.861876,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774310400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.1762,"preHourTrading":{"tag":"盘前","latestPrice":0.1799,"preClose":0.1762,"latestTime":"09:07 EDT","volume":202,"amount":35.63960134,"timestamp":1774271222897,"change":0.0037,"changeRate":0.020999,"amplitude":0.020999},"postHourTrading":{"tag":"盘后","latestPrice":0.1788,"preClose":0.181548,"latestTime":"17:25 EDT","volume":17,"amount":3.0450000499999996,"timestamp":1774301118524,"change":-0.002748,"changeRate":-0.015136,"amplitude":0.014872},"volumeRatio":1.114041,"impliedVol":2.7882,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/ITP/tweets","defaultTab":"tweets","newsList":[{"id":"2621081422","title":"Press Release: Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081422","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081422?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 23, 2026  -- Bionano Genomics, Inc.  today reported financial results for the fourth quarter and full year ended December 31, 2025.For the three-month period ended December 31, 2025, as compared to the same period of 2024:. -- Reported total revenue of $8.0 million, representing a decrease of 3%. from $8.2 million in the fourth quarter of 2024.-- The prior year period included $2.8 million in instrument revenue,compared to $2.7 million in the fourth quarter of 2025.-- Sold 7,554 nanochannel array flowcells in the fourth quarter of 2025,representing a decrease of 6% over the 8,058 flowcells sold in the fourth. -- Installed 9 new OGM systems and brought 6 back to reach an installed base. of 387 at quarter-end, representing a 4% increase over the 371 installed. systems reported at the end of the fourth quarter of 2024.-- Generated gross margin of 43%, compared to 42% for the fourth quarter of. 2024, and non-GAAP gross margin1 of 43%, compared to 42% for the fourth. -- Rep","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0661504455.SGD","ITP","BK4555","BK4099","BK4604","LU1894683264.USD","BNGO","BK4121","LU0553294199.USD","LU0738911758.USD","LU1003077747.HKD","03160","BK4588","BK4199","LU1894683348.USD","LU2637428348.USD","BK4208","BK4585","CMS","LU2346227817.USD","LU0545039389.USD","LU0949170772.SGD","TM","BK4575","LU2500361329.USD"],"gpt_icon":0},{"id":"2620460844","title":"Argenx’s Long‑Term ITP Study Reaches Completion, Sharpening the Outlook for Efgartigimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2620460844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620460844?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:30","pubTimestamp":1773678613,"startTime":"0","endTime":"0","summary":"Argenx ($ARGX) announced an update on their ongoing clinical study. Argenx’s latest update covers a long‑term Phase 3 trial of efgartigimod in adul...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenxs-long‑term-itp-study-reaches-completion-sharpening-the-outlook-for-efgartigimod?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenxs-long‑term-itp-study-reaches-completion-sharpening-the-outlook-for-efgartigimod?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2617411075","title":"Press Release: Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617411075","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617411075?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712000,"startTime":"0","endTime":"0","summary":"Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026. Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026. Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026. WELLESLEY HILLS, Mass., March 05, 2026  -- Climb Bio, Inc. , a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.previously treated patients with ITP is designed to evaluate safety,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4139","IND","BK4109","BK4199","CLYM","BK4539","ASH","BK4077","ITP","LU2463526074.USD"],"gpt_icon":0},{"id":"2614859660","title":"Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859660","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859660?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:00","pubTimestamp":1772197200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  27, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246483/0/en/Bionano-Symposium-2026-Concluded-with-9-Speakers-Describing-the-Breadth-of-Bionano-Solutions-and-Their-Potential-for-Use-on-a-Large-Scale.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIA","VGT","BK4023","BK4081","BK4585","BK4199","BK4588","ITP","BK4179","NGS","CN"],"gpt_icon":0},{"id":"2614044496","title":"10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044496","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044496?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:00","pubTimestamp":1772110800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitledOGM Making its Mark in Constitutional Gene","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245500/0/en/10-Presentations-on-Day-3-of-Bionano-Symposium-2026-Showcase-OGM-s-Utility-in-Unraveling-the-Complex-Puzzles-of-Constitutional-Genetic-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4207","ITP","BK4211","WGS","BK4589","BK4144","BK4196","CMA","BK4585","BK4199","WES","BK4590"],"gpt_icon":0},{"id":"2614807018","title":"argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614807018","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614807018?lang=en_us&edition=fundamental","pubTime":"2026-02-26 14:00","pubTimestamp":1772085600,"startTime":"0","endTime":"0","summary":"$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% yearoveryear growth Delivered $1.1 billion in operating income in 2025, marking first year of op","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245199/0/en/argenx-Reports-Full-Year-2025-Financial-Results-and-Provides-Fourth-Quarter-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","CMS","BK4211","LU2637428348.USD","LU2500361329.USD","BK4195","PRO","LU0553294199.USD","LU1003077747.HKD","PFS","LU0949170772.SGD","BK4208","LU0545039389.USD","LU1894683264.USD","LU0738911758.USD","BK4516","BK4588","ITP","LU1894683348.USD","BK4550","BK4199","LU0170899867.USD","BK4187","GD","BK4585","LU0661504455.SGD","BK4023","LU2346227817.USD"],"gpt_icon":0},{"id":"2613714299","title":"9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2613714299","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613714299?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:00","pubTimestamp":1771938000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignanci","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243479/0/en/9-Presentations-Kick-Off-Day-1-of-the-Bionano-Symposium-2026-Covering-Advances-in-Optical-Genome-Mapping-for-Hematologic-Malignancies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGS","LU0541501648.USD","ITP","LU0541502299.USD","BK4020","OCC","BK4115","BK4199","KT","BK4179"],"gpt_icon":0},{"id":"2610656991","title":"Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping","url":"https://stock-news.laohu8.com/highlight/detail?id=2610656991","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610656991?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:05","pubTimestamp":1770645900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  09, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234612/0/en/Bionano-Announces-Bionano-Symposium-2026-Global-Experts-Showcase-Advances-and-Innovation-in-Optical-Genome-Mapping.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP","OCC","BK4020"],"gpt_icon":0},{"id":"2609998473","title":"Takeda’s Mezagitamab ITP Extension Study: Long-Term Data That Matters for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2609998473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609998473?lang=en_us&edition=fundamental","pubTime":"2026-02-05 00:32","pubTimestamp":1770222764,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Study Overview: Takeda is running a Phase 3 continuation ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takedas-mezagitamab-itp-extension-study-long-term-data-that-matters-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takedas-mezagitamab-itp-extension-study-long-term-data-that-matters-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ISBC","ITP","BK4199"],"gpt_icon":0},{"id":"2608605362","title":"Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2608605362","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608605362?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:00","pubTimestamp":1770210000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  04, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the app","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3232006/0/en/Bionano-Announces-Publication-from-Sanford-Burnham-Prebys-Medical-Discovery-Institute-Describing-use-of-OGM-to-Detect-Genomic-Alterations-Introduced-by-Gene-Editing-Technologies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2602543576","title":"CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543576","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543576?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:36","pubTimestamp":1768224960,"startTime":"0","endTime":"0","summary":"-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216929/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2026-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","LU0251142724.SGD","LU0868494617.USD","BK4588","CRSP","LU1861558580.USD","AGT","LU0251131958.USD","FXI","BK4077","LU1917777945.USD","LU1974910355.USD","LU2023250504.SGD","LU1548497426.USD","BK4516","BK4149","BK4199","IE00BD6J9T35.USD","BK4230","LU1064131342.USD","LU2264538146.SGD","BK4597","BK4611","LU0942090050.USD","BK4139","BK4153","LU1861559042.SGD","IE00BSNM7G36.USD","LU0742534661.SGD","SCD","LU0048573561.USD","LU0868494708.USD","CAR","LU1988902786.USD","LU1720051108.HKD","BK4504","LU1720051017.SGD","LU0963586101.USD","LU2106854487.HKD","CAT","LU2237438978.USD","TG","LU2357305700.SGD","BK4520","BK4532","ITP","BK4090","SLE","BK4556","LDL"],"gpt_icon":0},{"id":"2602108435","title":"Press Release: Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2602108435","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602108435?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 12, 2026  -- Bionano Genomics, Inc.  today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended December 31, 2025.Fourth Quarter 2025 Preliminary, Unaudited Financial and Business Results. -- Total revenue is expected to be in the range of $7.8 million to $8.0. million, which is at the upper end of guidance and represents a decrease. in the range of 2% to 4% year-over-year.-- Nanochannel array flowcells sold in the fourth quarter of 2025 is. -- Total revenue is expected to be in the range of $28.4 million to $28.6. represents a decrease in the range of 7% to 8% year-over-year.resulted in an installed base of 387 OGM systems at year-end 2025,Cash, cash equivalents, available-for-sale securities, and restricted short-term investments were approximately $29.6 million as of December 31, 2025, of which $10.3 million is subject to certain restrictions.Bionano is in the process of completing its customa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4099","BK4588","TM","BNGO","BK4199","BK4604","BK4121","BK4585","03160","BK4575","BK4555"],"gpt_icon":0},{"id":"2602595531","title":"argenx Highlights 2026 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602595531","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602595531?lang=en_us&edition=fundamental","pubTime":"2026-01-12 14:00","pubTimestamp":1768197600,"startTime":"0","endTime":"0","summary":"Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales  VYVGART impact continues with approximately 19,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216531/0/en/argenx-Highlights-2026-Strategic-Priorities.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","CMS","BK4516","SMA","LU1003077747.HKD","ITP","LU0738911758.USD","LU0170899867.USD","BK4208","BK4588","LU2637428348.USD","LU0661504455.SGD","LU2500361329.USD","LU2346227817.USD","BK4217","BK4187","BK4585","LU0545039389.USD","LU1894683348.USD","BK4550","LU0949170772.SGD","LU1894683264.USD","BK4566","LU0553294199.USD","GD"],"gpt_icon":0},{"id":"2601698403","title":"Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601698403","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601698403?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873600,"startTime":"0","endTime":"0","summary":"First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215211/0/en/Climb-Bio-Announces-Pipeline-Progress-and-Strategic-Priorities-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4097","LU2463526074.USD","BK4077","BK4199","IND","LU2065732104.USD","ITP","ASH","BK4109","PRGS"],"gpt_icon":0},{"id":"1163901175","title":"Hangzhou's \"Six Little Dragons\" See Another IPO Emerge","url":"https://stock-news.laohu8.com/highlight/detail?id=1163901175","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163901175?lang=en_us&edition=fundamental","pubTime":"2026-01-05 15:41","pubTimestamp":1767598901,"startTime":"0","endTime":"0","summary":"Investing hinges on the insights of Golden Kirin analyst reports, which offer authority, professionalism, timeliness, and comprehensiveness to help you uncover potential thematic opportunities! The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2591301690","title":"argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2591301690","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591301690?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:00","pubTimestamp":1765778400,"startTime":"0","endTime":"0","summary":"15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205093/0/en/argenx-Provides-Update-on-UplighTED-Studies-of-Efgartigimod-SC-in-Thyroid-Eye-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2590287346","title":"Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2590287346","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590287346?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:30","pubTimestamp":1765283400,"startTime":"0","endTime":"0","summary":"Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202247/0/en/Novartis-ianalumab-significantly-extends-disease-control-in-patients-with-immune-thrombocytopenia-with-only-four-once-monthly-doses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077","ITP","LU2463526074.USD","ASH","ACR","BK4199","BK4110","BK4109"],"gpt_icon":0},{"id":"2588049548","title":"Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2588049548","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588049548?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Dec.  03, 2025  (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198844/0/en/Final-2026-Clinical-Lab-Fee-Schedule-Indicates-a-47-Increase-in-Payment-Determination-for-the-Category-I-CPT-Code-for-OGM-use-in-Hematologic-Malignancies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","BK4208","BK4199","CPT","CMS","LU1894683348.USD","LU2500361329.USD","BK4215","BK4588","LU0553294199.USD","ITP","LU1003077747.HKD","LU0545039389.USD","LU2346227817.USD","LU2637428348.USD","BK4585","LU0949170772.SGD","LU0661504455.SGD","LU0738911758.USD"],"gpt_icon":0},{"id":"2586441294","title":"Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2586441294","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586441294?lang=en_us&edition=fundamental","pubTime":"2025-11-25 14:15","pubTimestamp":1764051300,"startTime":"0","endTime":"0","summary":"Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings off","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194022/0/en/Novartis-data-underscore-pioneering-scientific-innovation-in-Hematology-and-Oncology-at-ASH-and-SABCS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","EBC","BK4581","BK4199","BC","BK4097","ITP","ET","BK4588","BK4590","BK4561","IS","OS","FUL","DDFS","BK4195","BK4190","PFS","BK4211","ASH","LU2463526074.USD","BK4109","BK4144","ASC"],"gpt_icon":0},{"id":"2583154511","title":"Press Release: Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583154511","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583154511?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067660,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 13, 2025  -- Bionano Genomics, Inc.  today reported financial results for the third quarter ended September 30, 2025.\"Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers. We believe our performance in the third quarter and year-to-date validates this strategic shift and demonstrates our turn toward sustainable growth as our business stabilizes. This quarter we delivered sustained margins, disciplined operating expense management, and increased utilization from routine users. We continue to see strong momentum in our key geographies and expanding utilization in new regions, including Japan, where researchers are leveraging optical genome mapping  to address complex questions in genetics. These developments strengthen our confidence in Bionano's long-term growth trajectory,\" commented Erik Holmlin, PhD, president and CEO of Bionano.For the thre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0553294199.USD","BK4208","LU0949170772.SGD","BNGO","LU2500361329.USD","BK4215","LU2065732104.USD","BK4588","BK4575","LU1894683264.USD","PRGS","LU0545039389.USD","CMS","ITP","LU0661504455.SGD","LU0738911758.USD","LU2637428348.USD","CPT","BK4585","LU2346227817.USD","LU1894683348.USD","BK4199","BK4097","LU1003077747.HKD","BK4121"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.itpackaging.cn","stockEarnings":[{"period":"1week","weight":-0.0721},{"period":"1month","weight":-0.1594},{"period":"3month","weight":-0.2515},{"period":"6month","weight":-0.268},{"period":"1year","weight":-0.3774},{"period":"ytd","weight":-0.1943}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IT Tech Packaging, Inc., together with its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company operates through three segments: Dongfang Paper, Tengsheng Paper, and Baoding Shengde. It offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. The company also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, it produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. The company is headquartered in Baoding, the People's' Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.411765,"avgChangeRate":0.000296},{"month":2,"riseRate":0.352941,"avgChangeRate":-0.00011},{"month":3,"riseRate":0.176471,"avgChangeRate":-0.027037},{"month":4,"riseRate":0.3125,"avgChangeRate":0.040688},{"month":5,"riseRate":0.3125,"avgChangeRate":-0.119651},{"month":6,"riseRate":0.3125,"avgChangeRate":-0.03945},{"month":7,"riseRate":0.466667,"avgChangeRate":-0.042617},{"month":8,"riseRate":0.125,"avgChangeRate":-0.076512},{"month":9,"riseRate":0.4375,"avgChangeRate":0.011462},{"month":10,"riseRate":0.375,"avgChangeRate":0.03598},{"month":11,"riseRate":0.375,"avgChangeRate":0.097377},{"month":12,"riseRate":0.125,"avgChangeRate":0.001262}],"exchange":"AMEX","name":"IT Tech Packaging Inc","nameEN":"IT Tech Packaging Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IT Tech Packaging Inc,ITP,IT Tech Packaging Inc股票,IT Tech Packaging Inc股票老虎,IT Tech Packaging Inc股票老虎国际,IT Tech Packaging Inc行情,IT Tech Packaging Inc股票行情,IT Tech Packaging Inc股价,IT Tech Packaging Inc股市,IT Tech Packaging Inc股票价格,IT Tech Packaging Inc股票交易,IT Tech Packaging Inc股票购买,IT Tech Packaging Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}